The economic costs of musculoskeletal care in the United States is approaching $800 billion or about 5.7% of annual GDP. (Ref) These costs are expected to increase significantly as our population ages. This is clearly not a sustainable path. A recent article published by the American Academy of Orthopedic Surgeons (AAOS) suggests the "early evidence is promising" for biologics to revolutionize musculoskeletal care. (AAOS Article in full)
Biologic orthopedic procedures are in the process of revolutionizing the options available for patients for difficult problems such as arthritis. It is an exciting time to execute on these point-of-care biologic treatments. Continued progress will demand hard work and innovation by elite motivated teams in order to produce transformative outcomes for patients.